Skip to content

Inspection Record

Blossom Pharmaceuticals — FDA 483 Findings

US FDAInspected 2025-04-11Published 2026-10-22 7 findingsLaboratory and QC controlsEquipment and facilityQuality unit oversightTraining and personnelProcess validation

Inspectors Kellia N HicksThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards and test procedures designed to assure that in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity.

2Equipment and facility

Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

3Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

4Training and personnel

Employees are not given training in the particular operations they perform as part of their function and current good manufacturing practices.

5Equipment and facility

Written procedures are not established and followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

6Process validation

Written production and process control procedures are not followed in the execution of production and process control functions and documented at the time of performance.

7Equipment and facility

Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable to facilitate cleaning, maintenance, and proper operations.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-22. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Blossom Pharmaceuticals company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.